Originally published In Press as doi:10.1074/jbc.M202016200 on April 5, 2002
J. Biol. Chem., Vol. 277, Issue 24, 21221-21230, June 14, 2002
Species-specific and Mutant MWFE Proteins
THEIR EFFECT ON THE ASSEMBLY OF A FUNCTIONAL MAMMALIAN
MITOCHONDRIAL COMPLEX I*
Nagendra
Yadava,
Prasanth
Potluri,
Erin N.
Smith,
Amina
Bisevac, and
Immo E.
Scheffler
From the Division of Biology and Center for Molecular Genetics,
University of California, San Diego,
La Jolla, California 92093-0322
Received for publication, February 28, 2002, and in revised form, March 27, 2002
 |
ABSTRACT |
The MWFE protein (70 amino acids) is highly
conserved in evolution, but the human protein (80% identical to
hamster) does not complement a null mutation in Chinese hamster cells.
We have identified a small protein segment where significant
differences exist between rodents and primates, illustrating very
specifically the need for compatibility of the nuclear and
mitochondrial genomes in the assembly of complex I. The segment between
amino acids 39 and 46 appears to be critical for species-specific
compatibility. Amino acid substitutions in this region were tested that
caused a reduction of activity of the hamster protein or converted the inactive human protein into a partially active one. Such mutations could be useful in making mice with partial complex I activity as
models for mitochondrial diseases. Their potential as dominant negative
mutants was explored. More deleterious mutations in the NDUFA1 gene were also characterized. A conservative
substitution, R50K, or a short C-terminal deletion makes the protein
completely inactive. In the absence of MWFE, no high molecular weight
complex was detectable by Blue Native-gel electrophoresis. The MWFE
protein itself is unstable in the absence of assembled mitochondrially encoded integral membrane proteins of complex I.
 |
INTRODUCTION |
Proton-translocating, multisubunit NADH-quinone oxidoreductases
(complex I) exist in mitochondria of most animals, plants, and fungi,
as well as in prokaryotes (1-11). The complex is absent in some fungi
such as the yeast Saccharomyces cerevisiae. The bacterial
complex has a total of 14 subunits (9, 12, 13) for which orthologues
can be identified in mammals and plants. These "core" subunits are
essential for the dehydrogenase activity, electron transport, and
proton translocation across the membrane (3). The complex I in mammals
and higher plants has at least 43 subunits. Seven of these are encoded
by the mitochondrial genome; they are made in the mitochondrial matrix
and assembled together with the other 36 subunits in a complex made up
of several major subdomains (10, 14-18). The integral membrane
subcomplex includes the mitochondrial peptides (ND1, 2, 3, 4, 4L, 5, and 6) and at least 10 nuclear encoded proteins (in higher organisms).
A second peripheral domain that may be further fractionated by mild
dissociation conditions extends into the mitochondrial matrix. It
includes the active site for the substrate NADH, a flavin
mononucleotide (FMN), as the hydride acceptor, and several of the
non-heme iron sulfur centers (9, 19). These two subcomplexes are
connected by a narrower neck or hinge region (20). Functionally the
subdomain in the matrix is an NADH dehydrogenase, and the connecting
fragment is related to multisubunit hydrogenases (8). Certain
combinations of detergents and fractionation techniques appear to
cleave the complex into three subcomplexes that may reflect this
functional differentiation. There are indications from work in
Neurospora crassa that subcomplexes appear to be assembled
independently in the matrix and in the inner membrane, respectively,
until they are joined to form the complete functional complex (10).
From a comparison of the prokaryotic and eukaryotic peptides, ~29
proteins in the mitochondrial complex have been described as
"accessory proteins" with functions yet to be defined (10, 21).
They may assist in the assembly of the complex, contribute to its
stability, have some role in regulation of activity, and may even carry
out biochemical functions such as the acyl carrier protein (22).
A collection of respiration-deficient Chinese hamster mutant cell lines
has been described by our laboratory, including at least three
complementation groups of cells with defects in complex I (23, 24). All
the mutations identified by us were in nuclear genes, and they were all
recessive in intra-species hybrids. The mutant CCL16-B2 has recently
been shown to be "complemented" by the matrix NADH dehydrogenase of
yeast, a single peptide encoded by the NDI1 gene (25). These
experiments established that the complex I defect is the only defect in
this mutant. Subsequently it was shown that the hamster
NDUFA1 cDNA complements the mutation (26). The human
NDUFA1 gene has been isolated and mapped on the X chromosome
by Zhuchenko et al. (27). It is a small gene (~5 kb) with
two introns (1.5 and 3 kb) encoding a peptide of 70 amino acids, the
MWFE protein. This protein is imported into mitochondria and assembled
in complex I without requiring proteolytic processing (22). It is
listed among the ~29 accessory proteins for which no function has
been established so far. Our results had shown that the MWFE protein is
essential for a functional complex I in mammalian mitochondria.
The growing interest in complex I deficiencies related to human
mitochondrial diseases (28-30) has been the impetus to map and
characterize all the nuclear genes encoding subunits of this complex,
because a number of human patients have been shown to suffer from
partial complex I deficiencies due to nuclear mutations (31-34).
Whereas severe mutations in mitochondrial structural genes can be
tolerated in heteroplasmic patients, nuclear gene mutations in patients
must be missense mutations causing a partial complex I deficiency. To
model complex I deficiencies, for example in the mouse, nuclear genes
and specific mutations must be identified that affect complex I
activity. In the present communication we have characterized a series
of such mutations in the NDUFA1 gene. Complementation of the
hamster null mutant CCL16-B2 with such mutant alleles restores partial
complex I activity.
 |
EXPERIMENTAL PROCEDURES |
Cell Lines and Cell Culture--
The parental Chinese hamster
cell lines and respiration-deficient mutants (res
)
derived from them have been described (see Ref. 35 for a review and
Ref. 36). They were routinely cultured in Dulbecco's modified Eagle's
medium with 4.5 mg/ml glucose
(DME1-Glu), 10% fetal calf
serum, nonessential amino acids, gentamycin, and fungizone. Under these
conditions even the respiration-deficient cell lines grow normally. To
distinguish res
from res+ cell lines, the
same medium was used with glucose replaced by 1 mg/ml galactose. It is
referred to as DME-Gal (37). The mouse cell lines (3A-20-4, 4A) with
defective ND5 and ND6 mitochondrial genes, respectively, were obtained
from Dr. A. Chomyn (18). Cells were harvested by trypsinization after
one wash with TD buffer (0.3% Tris, 0.8% NaCl, 0.038% KCl, 0.025%
Na2HPO4·12H2O, brought to pH 7.4 with HCl).
Plasmids and Genes--
The human NDUFA1 gene was
originally cloned and characterized by Zhuchenko et al.
(27). The bovine and mouse sequences had also been published. This has
permitted us to clone the corresponding cDNAs from hamster (26),
rat, and several other primates by an approach based on reverse
transcriptase-PCR using conserved oligonucleotide sequences (26). Crude
RNA extracts from fibroblasts of lemur, chimpanzee, and gorilla were
obtained from Dr. Oliver Ryder at the San Diego Zoo. The PCR products
were cloned into pGEM-T vector (Promega) by T-A overhang cloning. The
nucleotide sequence was determined by a multiplex dideoxy chain
termination method (University of California, San Diego, Cancer
Center). To determine the nature of mutations in cell lines V79-G20 and
V79-G14, the NDUFA1 cDNAs were cloned as
described above.
Site-directed mutagenesis was carried out by using a "megaprimer"
PCR method (39). The mutagenesis primers used are as follows: A42, 5'-CACTGGTAACCAAGGCGACCAACT-3'; A41/42,
5'-ACCACTGGTAACCAAAGCGACCAACTCT-3'; A40/44/46,
5'-TTTCCATCAAACTCCAGTGGTAACGAAGGTGACCAACTCT-3'; and U41/42,
5'-CCAGTGATACCGAAGATGAGCAACCCTTTT-3'. The "A" series represent mutations at the corresponding
positions in the hamster protein, and the "U" series represent
mutations at the indicated positions in the human protein. After
cloning into the expression vector pBK-CMV (Stratagene, La Jolla, CA), the mutations in the cDNAs were confirmed by sequencing. The
A40/44/46 primer yielded only the mutations at positions 40 and 44. As
an alternative, a pTRIDENT14 vector ((40); Cistronics Cell Technology GmbH, Zurich, Switzerland) with an EF1
promoter was modified with a
neomycin cassette as the third cistron. The neoR gene
from the pIRESneo vector (CLONTECH) in an
SspI-SmaI fragment (3250 bp) was inserted into
the SspI-SwaI fragment from the pTRIDENT-14 vector. The resulting construct was designated as pTRIDENT14-neo vector. The MWFE coding sequences were cloned into the first cistron site, leaving two internal ribosome entry sites between the
NDUFA1 and neomycin coding sequences.
A PCR-based approach was used to tag the MWFE protein at the C terminus
with the HA epitope. The primers used are as follows: HaNDF1
(with EcoRI site),
5'-CCGgaattcAACGGTGCGGAGATG-3'; MWFE.HaR1 (with
BglII site),
5'-CAagatctCTAGGATCCGGCGTAGTCAGGCACGTCGTAAGGGTAACTAGTGTCAATGTTCTCCAAGCCCC-3'; and MWFE.HaR2 (with BglII site),
5'-CAagatctTTAGGATCCGGCGTAGTCAGGCACGTCGTAAGGGTAACTGTCAATGTTCTCCAAGCCCTT-3'. The various normal and mutant NDUFA1 cDNAs were
PCR-amplified using HaNDF1 and MWFE.HaR1 (for hamster) or MWFE.HaR2
(for mouse and human) and cloned into pTRIDENT14-neo using the unique
EcoRI site. EcoRI-BglII fragments from
PCR were ligated into EcoRI-digested and calf intestinal
phosphatase-treated pTRIDENT14-neo for the first linkage; after filling
in the ends, blunt ends were ligated to close the circle. The positive
clones were screened using SpeI digestion, and the final
constructs were verified by sequencing.
Northern analysis was performed as described, using a hamster
NDUFA1 cDNA probe (26). A probe for citrate synthase
mRNA was made by reverse transcriptase-PCR with
oligonucleotide primers CS.F1 (5'-ATGGCTTTACTTACTGCGGC-3') and
CS.R1 (5'-CACATGGGAAGGCAGAGCTG-3') which amplify a 453-bp human
cDNA beginning with the ATG start codon.
Complementation Tests--
The cells were transfected by
incubating ~1-4 × 106 cells per plate with 10 µg
of plasmid and polyethyleneimine as carrier as described (41). After a
48-h incubation in DME-Glu, G418 (Calbiochem) was added to some plates
(selection for neo resistance), and in others the medium was changed to
DME-Gal for a direct selection of the res+ phenotype as
described (37). The G418-resistant colonies were marked on the plate
after about 2 weeks and tested for their
res
/res+ phenotype by exposure to DME-Gal
(23). The polycistronic constructs were transfected into cells using
SuperFect reagent according to the manufacturer's instructions
(Qiagen). The transfection mixture for CCL16-B2 (res
)
cells constituted 0.5 µg of DNA and 5 µl of SuperFect; for CCL16-B1 (res+) cells it was 2 µg of DNA and 10 µl of SuperFect.
Measurement of Respiratory Activities--
The respiratory chain
activities of various cells were measured as described (25). The cells
were harvested by trypsinization, collected by centrifugation (350 × g), and resuspended in 1× HSM buffer (20 mM
Hepes, pH 7.1, 250 mM sucrose, 10 mM
MgCl2) at density 2 × 107/ml. The cells
were treated with 100 µg/ml digitonin until more than 90% of the
cells are stained by trypan blue. After ~5 min of digitonin treatment
at 4 °C, the cell suspension was diluted 10-fold with HSM buffer,
and the cells were harvested by centrifugation. Subsequently, cells
were washed once with the same medium and resuspended at 3 × 107 cells/ml. The total protein content was measured by
Bradford microassay, and ~5-6 mg of cell suspension was used per
assay. Oxygen consumption was measured polarographically in a 2.2-ml metabolic chamber with a water jacket maintained at 37 °C by using a
Clark-type oxygen electrode. Substrates, inhibitors, etc. could be
added via a capillary opening using microsyringes as described previously (26). Respiratory activity in
2,4-dinitrophenoluncoupled mitochondria (3-4 mg/assay) was
measured essentially as above.
Isolation of Mitochondria and Mitochondrial
Fractions--
Mitochondria were isolated from cells essentially
according to Trounce et al. (42). Mitochondrial fractions
were prepared as follows. Approximately 1 × 109 cells
(CCL16-B1, CCL16-B2, and NDUAF1-transfected cells) were washed twice with TD buffer and harvested by trypsinization. The pellets were suspended in 5 ml of SM buffer (50 mM
Tris-HCl, pH 7.4, 0.25 M sucrose, 2 mM EDTA)
and homogenized using a tightly fitting Dounce homogenizer (30-35
up/down strokes). The homogenate was centrifuged twice at 625 × g for 10 min at 4 °C in order to remove unbroken cells
and nuclei. The supernatant was centrifuged at 10,000 × g for 20 min at 4 °C. The mitochondrial pellet was suspended in 0.1 ml of the SM buffer. This fraction is designated as
the mitochondrial fraction.
Immunochemical Assays and Antibodies--
Cells were grown and
harvested as above. The lysis of cells was carried out in buffer (50 mM Tris-HCl, pH 7.4, 2 mM phenylmethylsulfonyl fluoride, 2 mM EDTA, and protease inhibitor mixture P8340
from Sigma) by 3 cycles of freeze-thaw in liquid nitrogen and 3 bursts of sonication. Protein samples (between 50 and 100 mg) were separated by SDS-PAGE and transferred to Immobilon-P (0.45 µm) or
polyvinylidene difluoride (0.1 µm) membranes. Anti-MWFE and anti-ERK2
were used at 1:5000 dilution, and the other antibodies were used at
1:1000 dilution. Horseradish peroxidase-conjugated secondary antibodies (anti-rabbit or anti-mouse) were used at 1:5000 dilution, and signals
on the immunoblots were detected using an enhanced chemiluminescence system (ECL+Plus from Amersham Biosciences).
The antibody against the MWFE protein was generated by immunizing
rabbits with two synthetic peptides corresponding to two major segments
of the hydrophilic domain of the protein (amino acids 29-40 and
59-70; see Fig. 1A). Affinity-purified antibodies were
prepared by a commercial manufacturer (HTI BioProducts, Inc. Ramona,
CA). Antibodies specific to bovine complex I subunits (23 (TYKY) and 51 kDa) were generous gifts from Drs. Y. Hatefi and T. Yagi (The Scripps
Research Institute) (1, 13, 43, 44). Dr. R. A. Capaldi (Institute
of Molecular Biology, Eugene, OR) generously provided mouse monoclonal
antibodies against the 39- and 30-kDa subunits of complex I (45), and
Dr. M. David (Division of Biology, University of California, San Diego)
generously gave anti-ERK2 antibody. Sources of other antibodies were as
follows: anti-porin from Calbiochem, anti-cytc from BD PharMingen,
anti-HA from Covance Babco, and anti-mouse and anti-rabbit secondary
antibodies from Bio-Rad and Amersham Biosciences, respectively.
Blue Native-PAGE--
Blue native-gel electrophoresis of
mitochondrial respiratory complexes was performed as described by
Schagger (46). The mitochondrial pellets equivalent to 400 µg of
protein were solubilized with 800 µg of
dodecyl-
-D-maltoside (Sigma) in 5 mM
6-aminohexanoic acid, 50 mM imidazole HCl, pH 7.0, and 10%
glycerol. To the solubilized samples Coomassie Brilliant Blue G-250
(Serva) was added at a dye/detergent ratio of 1:5 g/g. A 3.5-13%
acrylamide gradient gel was used for electrophoresis.
The histochemical assays on the BN-PAGE gels were performed according
to Dabbeni-Sala et al. (47) by incubating the gel slices
with 2 mM Tris-HCl, pH 7.4, 0.1 mg/ml NADH, and 2.5 mg/ml nitro blue tetrazolium (Sigma) for complex I. Complex V (ATPase) activity was measured by incubating the gel slices overnight in 35 mM Tris, 270 mM glycine, pH 7.8, 14 mM MgSO4, 0.2%
Pb(NO3)2, and 8 mM ATP at room temperature.
Other Reagents--
The transfection reagents were
polyethyleneimine from Sigma and SuperFect from Qiagen (Germany). All
other reagents were of the highest grade available.
 |
RESULTS |
Mutant Alleles of NDUFA1 cDNA--
The MWFE protein from
diverse mammalian species, from other vertebrates (Xenopus
laevis), and even from plants (rice) is highly conserved
(Fig. 1A). In all the species
so far examined, the protein is precisely 70 residues long, with two
distinct domains. A predicted transmembrane region consisting of the
first ~24 amino acids is followed by a highly charged domain of ~45
amino acids. Because there is no further processing (22, 48, 49), the
N-terminal sequence must also act as the mitochondrial targeting
sequence. The negative charge at position 4 is unusual; it is also
highly conserved. The orientation of the protein in the membrane has not been firmly established, but preliminary results suggest that the
hydrophilic domain of the MWFE protein extends into the intermembrane space.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 1.
Top, sequence conservation of the MWFE
protein in some representative species. The boxed region
emphasizes the significant amino acid differences between rodent and
primate proteins. Bottom, sequence differences in mutants
isolated in tissue culture selections (CCL16-B2, V79-G20, and V79-G14)
and mutant proteins created by site-directed mutagenesis. The
underlined short peptides were used in combination for
the immunization of rabbits and the production of anti-MWFE
antibody. Only the C-terminal peptide appears to be recognized by the
antibody (see text).
|
|
Our previous studies have shown that human NDUFA1 cDNA
does not complement the mutation in the hamster gene despite the high degree of sequence conservation in the protein (26). When additional primate and rodent sequences were determined and compared, significant differences between amino acids 39 and 46 were found to distinguish primates from rodents. Most notable is the difference in the spacing of
the two positive charges in this segment; they are separated by one
amino acid in the hamster and by three amino acids in primates. The
mouse MWFE protein is missing a positive side chain in this region but
mouse cDNA could complement the hamster mutation at a slightly
lower efficiency than hamster cDNA (26) (Fig. 6A). Differences in almost all other positions represent highly conservative amino acid substitutions in the hydrophobic domain.
Several mutant alleles of the NDUFA1 gene were isolated
during the original mutant selection in tissue culture (CCL16-B2, V79-G14, V79-G20, see Fig. 1B) (37). The CCL16-B2 mutant has been described previously; a large internal deletion in the
NDUFA1 gene causes the resulting protein to be severely
truncated and altered by frame shifting (26). Another mutant allele in
the same complementation group was characterized from the mutant cell line V79-G14. Sequencing of several NDUFA1 cDNAs
obtained by reverse transcriptase-PCR revealed a small insertion in the
last exon; the insertion leads to the formation of a MWFE protein that
is slightly shorter (66 amino acids), and the last two amino acids are
different from the original sequence. In the V79-G20 mutant a point
mutation converted an arginine to a lysine codon. This R50K mutation
was originally found in an independently isolated clone of
respiration-deficient mutants, V79-G20, that could be complemented with
wild type NDUFA1 cDNA. The severe loss of activity from
this very conservative amino acid substitution was surprising, but the
result was confirmed by making the same mutation in wild type cDNA
by site-directed mutagenesis. It should be noted that the arginine at
position 50 is found in all the proteins sequenced so far, including
plants and mammals. The synthetic V79-G20 cDNA also failed to
complement the CCL16-B2 cells, confirming the somatic cell hybrid data
(23).
Site-specific mutagenesis was carried out with wild type hamster and
human NDUFA1 cDNAs to introduce one or two amino acid substitutions, changing the hamster sequence toward the human or the
human sequence toward hamster in the narrow segment where the major
species differences are observed (Fig. 1B). The
corresponding cDNAs were cloned into mammalian expression vectors
("Experimental Procedures"), and stable, transfected hamster
CCL16-B2 mutant cell lines were established. Cells were selected in
DME-Glu medium containing G418. Alternatively, a direct selection for a
functional, complementing NDUFA1 cDNA could be made in
DME-Gal. The complemented cell lines were designated B2-A42, B2-A41/42,
B2-A40/44, and B2-U41/42 depending upon the type of the MWFE mutation
(Fig. 1B). B2-A41/42 resembles the mouse protein with a
positive charge removed at position 41; in B2-U41/42 an additional
positive charge has been added to the human protein at position 42. Thus, the total number of positive charges in this very limited region
varies from 1 to 3 in the three mutant proteins.
Our investigation of the complemented CCL16-B2 cells started with
measurements of growth rates in DME-Gal medium, a condition requiring
respiration and oxidative phosphorylation. The results show that the
complemented cell lines B2-A42, B2-A41/42, and B2-A40/44 expressing
mutated hamster MWFE protein grew slower compared with wild type
CCL16-B1 cells in this medium (Fig. 2).
The growth impairment was variable, depending on the type of mutation
made in the MWFE protein (Fig. 2). In the "A series" the most
severe impairment (~50%) is due to the A41/42 double mutation in the
hamster sequence. More interesting and less predictable was the
observation that the inactive human MWFE protein could be turned into a
partially complementing protein by the alteration of two amino acids
(U41/42). In this protein there are three positively charged amino acid side chains in the small interval. Clearly, a detailed evaluation of
the amino acid substitutions and their effect on activity must await
the completion of the crystal structure of complex I.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 2.
Comparisons of growth rates of wild type
CCL16-B1 (B1), null mutant CCL16-B2
(B2), and complemented cell lines
(B2-A42, B2-A41/42, B2-A40/44, and
B2-U41/42). The growth was measured under restrictive
conditions (DME-Gal) where cells must have the capacity to
respire.
|
|
Measurements of Complex I Activity--
Measurements of
respiration were made with digitonin-permeabilized cells and with
isolated mitochondria. The successive addition of different substrates
and specific inhibitors allowed measurements of the activity of
individual complexes. Rotenone-sensitive, malate + glutamate-dependent respiration reflects complex I
activity; complex II/III activity can be measured with succinate as
substrate and the use of either malonate or antimycin as inhibitors,
and TMPD/ascorbate can be used as substrates to measure complex
IV activity. Results from the first series of transfectants with monocistronic transcripts are shown in Fig.
3. Compared with wild type cells, the
CCL16-B2 cells had typically less than 10% complex I activity, and an
inactive human protein could be modified at two positions to acquire
partial activity (Fig. 3A); the mutants had intermediate
activity levels that were roughly correlated with their relative growth
rates in DME-Gal medium (Fig. 3B). The reduction in complex
I activity was most severe in the double mutants B2-A41/42 and
B2-U1/42. The reduction in complex I activity observed in whole cell
assays was further confirmed by assaying the complex I activity in
isolated mitochondria. Data from a representative cell line B2-A41/42
are shown in Fig. 3C. The activities were all normalized to
total cellular protein or to total mitochondrial protein, respectively.
By this means of normalization, some of the mutant cells had apparently
elevated complex II/III levels. However, the significance of this
variation is difficult to assess. These individual, selected
populations of cells are not exactly diploid and isogenic. It is
significant that the relative differences in complex I activity were
observed in both whole cells and in isolated mitochondria, although a
normalization to different protein subsets was employed in this
comparison.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 3.
Polarographic measurements of oxygen
consumption with digitonin-permeabilized whole cells (A
and B) or isolated mitochondria (C)
from various cell lines (see Fig. 2). A, respiratory
activities: rotenone-sensitive glutamate/malate driven (complex
I), antimycin-sensitive succinate-driven (complex
II/III), and KCN-sensitive TMPD/ascorbate-driven
(complex IV) are shown; B, the "total"
activity refers to the respiration before the addition of rotenone.
About 5-6 mg of permeabilized whole cells or 3-4 mg of isolated
mitochondria were used per assay. Activities of different complexes in
wild type cells were set at 100% for comparison.
|
|
The Expression of MWFE Proteins and Complex I Activity in Various
Mutants of Chinese Hamster Fibroblasts--
A polyclonal anti-MWFE
antibody was made in rabbits by immunization with two small peptides
from the hydrophilic domain of the MWFE protein (see "Experimental
Procedures" and Fig. 1B). To investigate the specificity
and cross-reactivity of this antibody, whole cell lysates from hamster,
mouse, and human cell lines were examined by Western blotting (Fig.
4A). The antibody
cross-reacted with the corresponding mouse and human proteins, but the
interaction appeared weaker with the human protein. Independent
experiments established that all the antigenic protein found in whole
cell lysates was membrane/mitochondria-associated, and it had the
expected low molecular weight (results not shown).

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 4.
Characterization of anti-MWFE antibody and
analysis of MWFE expression by Western blotting in mutants isolated in
tissue culture selections. Whole cell extracts (100 µg) from
indicated cell lines were separated by SDS-PAGE, blotted on
polyvinylidene difluoride membranes, and probed with various
antibodies. A, detection MWFE proteins from hamster, mouse,
and human cells using anti-MWFE antibody generated by us. Cyt
c and hsp60 (other mitochondrial proteins) and
ERK2 (a cytoplasmic protein) were also probed using specific
antibodies. B, expression of MWFE protein in Chinese hamster
wild type (CCL16-B1), the null mutant (CCL16-B2),
and other mutants in the same complementation group
(V79-G20, V79-G14, and V79-G42). The
V79-G4 mutant has a complex I deficiency in an unrelated gene, and the
V79-G7 mutant is severely impaired in mitochondrial protein
synthesis.
|
|
Shown in Fig. 4B are Western blots with whole cell lysates
from wild type CCL16-B1 cells, from various mutant cells of
complementation group I (CCL16-B2, V79-G14, V79-G20, and V79-G42), and
from additional mutant cell lines in different complementation groups
(V79-G4 and V79-G7) (23). The V79-G7 mutant cells were included in this analysis because mitochondrial protein synthesis is absent in this
mutant (36), and all seven mitochondrially encoded subunits of complex
I are missing. The protein is found in V79-G4 cells (complementation
group II). V79-G7 cells have a normal NDUFA1 gene and can
complement the CCL16-B2 mutant in somatic cell hybrids (23). The
absence of a signal therefore indicates that the MWFE protein must be
highly unstable when it is imported into mitochondria but not assembled
in a complex I without mitochondrially encoded proteins. This
observation also suggests that an excess of MWFE protein would not
accumulate significantly in mitochondria as a free integral inner
membrane protein, for example when overexpressed from a transgene with
a highly active promoter. The expression of MWFE from polycistronic
pTRIDENT14-neo in V79-G7 cells is also not detectable on a Western blot
(results not shown). From the characterization of the nature of the
mutation (Fig. 1B), the absence of MWFE protein in the
CCL16-B2 cells could be anticipated. The MWFE band was also missing
from the three other mutant cell lines V79-G14, V79-G20, and V79-G42.
The loss of activity due to the R50K mutation (in V79-G20) appears to
be due to a failure of this mutant protein to be incorporated into
complex I. The mutated site is outside of the regions for the two
peptides used in the immunization. The deletion of four C-terminal
amino acids (V79-G14) is equally deleterious for activity and for
detection on the Western blot, although it is not possible to determine whether the truncated protein fails to be incorporated into the complex
or whether the truncation has destroyed the major antigenic determinant
at the C terminus. The precise alteration in the V79-G42 mutant allele
has not yet been determined.
Western blots from CCL16-B2 cells complemented with different alleles
of the NDUFA1 cDNA are shown in Fig.
5. By using the lane with B2-MWFE (wild
type) extracts as a basis for comparison, the MWFE protein levels were
comparable in all the CCL16-B2 cells complemented with altered hamster
MWFE proteins that diminished complex I activity. The weaker signal
with the U41/42 mutation is likely to be due to the reduced
antigenicity of the human MWFE protein, because an arginine at position
64 is replaced by a lysine. One conclusion is that the mutant proteins
are fully incorporated into complex I and hence stabilized. The
presence or absence of MWFE protein was clearly correlated with the
presence or absence of complex I activity, but the precision of the
quantitation by Western analysis was not sufficient to determine
unambiguously whether the reduced activity observed in the presence of
the mutant alleles was due to a reduced specific activity of the
complex or due to an effect on the kinetics of the assembly of active complex I.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 5.
Analysis of MWFE expression in complemented
cell lines by Western blotting (see Fig. 4). A,
comparison of MWFE abundance in wild type CCL16-B1 (B1),
null cells CCL16-B2 (B2), and null cells complemented with
wild type (B2-MWFE) or mutant proteins
(B2-A42, B2-A41/42, B2-A40/44, and
B2-U41/42). MWFE and Cyt c were detected using anti-MWFE and
anti-Cyt c antibodies, respectively. B, analysis of
HA-tagged MWFE using monoclonal antibody (HA.11) directed against the
HA epitope. Mitochondrial proteins porin (outer membrane), 39 and 30 kDa, and MWFE (complex I proteins) were detected using specific
antibodies. As expected MWFE-HA migrates slower compared with MWFE on
SDS-PAGE. Addition of the HA tag at the C terminus also completely
abolishes recognition by the anti-MWFE antibody.
|
|
HA-tagged MWFE Protein Complements the Null Mutant--
To
establish the topology of the MWFE protein in the membrane and to
follow such a protein in transgenic cells (and animals), it was
desirable to mark this protein with an epitope tag. An MWFE protein
with the green fluorescent protein at the C-terminal yielded green
mitochondria but did not complement CCL16-B2 cells (results not shown).
However, when the much shorter hemagglutinin (HA) peptide
(TSYPYDVPDYAGS) was used as epitope tag at the C terminus of
the wild type protein, functional complementation of the null mutation
and stabilization of the MWFE-HA protein could be achieved (Fig.
5B). Subsequently, several of the mutant alleles were also
constructed with the HA tag at the C terminus. In these constructs the
MWFE-HA protein was expressed from the pTRIDENT14-neo vector as the
first cistron of a multicistronic mRNA ("Experimental
Procedures"). In all cases, transfected cells were selected in
DME-Glu in the presence of G418, and experiments were performed with
stable, transformed cells.
The observation that the MWFE-HA protein could complement the CCL16-B2
mutant was interesting, because it suggested that the C-terminal
carboxyl group was not absolutely required, although the results with
the V79-G14 allele had indicated that a small deletion at that end
could not be tolerated. A comparison of the wild type MWFE protein with
the wild type MWFE-HA protein in CCL16-B2 cells revealed relatively
small differences in complex I activity. The HA-tagged protein can be
detected on Western blots, and the shift in mobility is as expected
from the addition of 13 amino acids to the very small MWFE protein.
However, it appears that the C-terminal addition completely destroyed
the antigenic determinant(s) for the anti-MWFE antibody (Fig.
5B). The latter was raised against a mixture of two peptides
("Experimental Procedures"), one of which included the terminal 11 amino acids. It is therefore likely that the interior peptide is not
recognized by this antibody.
The expression and function of the HA-tagged MWFE from a polycistronic
vector was tested in hamster and human cells. As before, the mutant
U41/42-HA allele and the mouse MWFE-HA yielded reduced complex I
activities compared with the wild type hamster MWFE-HA (Fig.
6A). When complex I activity
was observed, MWFE-HA could be detected on Western blots (Fig.
6B), with the human MWFE-HA protein being undetectable. When
a series of the same constructs were transfected into human HT1080
cells, only the human MWFE-HA protein was stabilized (by incorporation
into human complex I), but the hamster MWFE-HA, A41/42-HA, and
U41/42-HA proteins were unstable (Fig. 6B). Two amino acid
changes in the human protein made it active in hamster mitochondria but
inactive in human mitochondria.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 6.
A, polarographic measurements of oxygen
consumption by CCL16-B2 cells complemented with HA-tagged hamster wild
type (MWFE), mutant (U41/42), and mouse MWFE (mouse) expressed from
polycistronic pTRIDENT14-neo vector (see "Experimental
Procedures"). Digitonin-permeabilized whole cells were used for
polarographic measurements (see Fig. 3, A and B).
B, expression analysis of HA-tagged mutant (A41/42 and
U41/42) and wild type MWFE proteins from hamster, human, and mouse in
Chinese hamster CCL16-B2 and human HT1080 cell lines. The wild type
protein of a species is indicated by species name itself. A41/42 and
U41/42 are double mutants of hamster and human MWFE proteins,
respectively (see "Experimental Procedures"). 100 µg of whole
cell extracts from transfected cell lines were separated on SDS-PAGE
and transferred on polyvinylidene difluoride membrane, and MWFE-HA was
detected using monoclonal antibody HA.11. Other indicated proteins were
detected using specific antibodies.
|
|
Overexpression of the MWFE Protein in Wild Type Cells--
If a
mutant MWFE protein causes a reduction in the specific activity of
complex I, a mutant allele might act as a dominant negative allele when
overexpressed in a wild type background. Experiments were performed
with the polycistronic pTRIDENT14-neo constructs expressing HA-tagged
mutant and wild type proteins in stable cell lines. Selections of
stable transformed cell lines were made in DME-Glu with G418, and
subsequently individual clones or pooled populations were characterized.
The analysis of individual clones revealed some surprises, and the
results with wild type CCL16-B1 cells transfected with the A41/42-HA
allele will serve as examples. Western blots with whole cell extracts
and Northern blots with total RNA were made from a series of individual
clones (Fig. 7A). Several
conclusions stand out. 1) There is significant clonal variation in the
Western blots with regard to complex I proteins; other mitochondrial
proteins (porin) are present at comparable levels. Differences in the
level of MWFE and MWFE-HA bands are particularly striking. It should be
pointed out that whole cell extracts were used for these Western blots,
and although the MWFE and MWFE-HA bands reflect the amount of assembled
complex I, the 30- and 39-kDa bands include the unassembled fractions
of these proteins that can also be seen in V79-G7 cells (results not
shown) and in
o cells (45). 2) The ratio of wild type
MWFE from the endogenous gene to HA-tagged MWFE expressed from the
transgene is also variable, but in all clones with wild type MWFE-HA
the transgenic protein is higher, whereas the transgenic mutant
A41/42-HA protein is relatively lower. This may reflect the relative
stabilities or the relative rates at which these proteins are
incorporated into complex I. Only relative signals can be compared,
because two different non-cross-reacting antibodies were used for each
protein species. 3) A difference in the HA-tagged MWFE proteins could be the result of a different dose of the transgene in the clones. On
the other hand, different doses of transgene could not account for
elevated or reduced levels of the endogenous MWFE protein. A Northern
blot (Fig. 7B) reveals fairly constant levels of
NDUFA1 mRNA from the endogenous gene, as expected.
Levels of the polycistronic transcript were significantly higher (the
same probe labeled both transcripts) and more variable. The mRNA
for citrate synthase served as a loading control. The far right
panels of Fig. 7B also show the citrate synthase and
NDUFA1 bands from untransfected wild type CCL16-B1 and
mutant CCL16-B2 cells. As described before, the CCL16-B2
NDUFA1 mRNA with an internal deletion is less stable and
less abundant.

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 7.
Overexpression of HA-tagged wild type
(MWFE-HA) and mutant (A41/42-HA) proteins
in CCL16-B1 cells. A, clonal analysis of endogenous and
HA-tagged MWFE by Western blotting. Anti-MWFE and anti-HA antibodies
were used to detect endogenous and transgenic MWFE, respectively. As
internal controls, antibodies against an outer membrane protein (porin)
and two complex I proteins (30 and 39 kDa) were also used. Clones
B1-MWFE-HA.2 and B1-A41/42-HA.3 and B1-A41/42-HA.8 were subjected to
further analysis described in Fig. 8 (and in the text). B,
Northern analysis with total RNA from the clones shown in A.
Citrate synthase mRNA was used as a loading control. The
NDUFA1 probe can detect both the endogenous
NDUFA1 mRNA and the larger poly-cistronic mRNA
expressed from the transgene. The strengths of the signals directly
reflect the relative levels of the two transcripts. On the right
side the signals from untransfected wild type CCL16-B1 (B1) and
null mutant cells CCL16-B2 (B2) are shown, first after an exposure
comparable with that for the permanently transfected cells and then
after a prolonged exposure. The NDUFA1 mRNA from mutant
is slightly smaller and less stable due to a premature stop
codon.
|
|
Three clones were selected for a more detailed analysis: B1-MWFE-HA.2,
B1-A41/42-HA.3, and B1-A41/42-HA.8. Clones B1-MWFE-HA.2 and
B1-A41/42-HA.8 were comparable with respect to transcript levels but
very different in the levels of protein. B1-A41/42-HA.3 had
significantly more of either endogenous or transgenic protein, and the
transcript levels appeared elevated from both the endogenous gene and
transgene; citrate synthase mRNA levels were still comparable.
Growth rate comparisons in DME-Gal showed clone B1-A41/42-HA.8 to grow
at half the rate compared with wild type protein overexpressing B1-MWFE-HA.2 cells, whereas a second clone, B1-A41/42-HA.3, grew at
almost twice the rate (Fig.
8A). The faster growing clone
clearly had more MWFE and A41/42-HA proteins, and if these levels
reflect the amount of complex I in mitochondria, the observed
differences in growth rates in DME-Gal are due to differences in
complex I activity in these cells.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 8.
Analysis of selected clones overexpressing
HA-tagged MWFE proteins (B1-MWFE-HA.2,
B1-A41/42-HA.3, and B1-A41/42-HA.8; see Fig. 7).
A, comparison of the growth rates. B,
histochemical and Western analysis of complex I assembly in wild type
CCL16-B1 (B1) and null mutant CCL16-B2 (B2) on
BN-PAGE. C, histochemical and Western analysis of A41/42-HA
incorporation into complex I in clones B1-A41/42-HA.3 and
B1-A41/42-HA.8.
|
|
It should be noted that in the faster growing clone the levels of both
the endogenous and the HA-tagged MWFE protein are elevated, reflecting
total complex I levels. BN-PAGE was used to verify these assumptions.
Wild type CCL16-B1 and the null mutant CCL16-B2 cells were also
investigated, yielding two novel results. A histochemical assay
revealed activity in the lane with wild type mitochondrial extracts
associated with a band at ~900 kDa. This activity was not sensitive
to rotenone, suggesting the nitro blue tetrazolium accepts electrons
from a site unaffected by this inhibitor. No significant activity was
found anywhere in the lane with mutant extracts. Several proteins (51, 39, and 23 kDa and others not shown) were found in the ~900-kDa band
from wild type extracts, indicating an intact complex I, but these
proteins were absent in the lane with mutant extract. A further
analysis of the fate of these proteins in the mutant is in progress,
because they are detectable on standard Western blots from
mitochondrial membranes (26).
Mitochondria from wild type (CCL16-B1) and clones B1-41/42-HA.8 and
B1-41/42-HA.3 were similarly analyzed by BN-PAGE, followed by a
histochemical assay and Western blotting. As expected, clone B1-41/42-HA.3 had appreciably more activity compared with clone B1-41/42-HA.8. An assay for complex V (ATPase) on the same gel shows
comparable activities, and from the staining and appearance of various
other bands one can conclude that equivalent amounts of mitochondrial
extracts were loaded in all lanes. Western analysis with anti-HA and
anti-MWFE antibodies confirmed that both wild type and mutant MWFE
proteins were associated with complex I. The signals from anti-HA,
anti-MWFE, and anti-39-kDa antibodies indicated that the observed
differences in complex I activity were reflected in the differences of
the protein bands. Clearly, the clones differed greatly in the amounts
of complex I (see "Discussion" for some further interpretations).
In these Western blots the 39-kDa band represents only those subunits
in the complete, assembled complex I, and hence the relative band
intensities are different from those in Fig. 7A.
 |
DISCUSSION |
Previous work from this laboratory (26) and the present
work demonstrate that the small integral membrane protein, MWFE, encoded by the X-linked NDUFA1 gene, is absolutely
required for activity of complex I. Here we demonstrate that MWFE is
not only required for NADH-quinone oxidoreductase activity, but it is
also absolutely required for stable assembly of an ~900-kDa complex with NADH dehydrogenase activity, measured on BN-PAGE with nitro blue
tetrazolium as electron acceptor.
The MWFE protein is most likely anchored in the inner membrane with its
N-terminal domain, leaving a short domain of ~45 amino acids with 12 positive and 5 negative charges for interactions with other subunits.
The protein is highly conserved in evolution in animals as well as
plants. At the same time it was striking that the human protein could
not complement a null mutation in Chinese hamster cells. We believe
that this is a specific example illustrating observations made over the
past decades that mitochondria from one mammal cannot be functional in
a cell with the nucleus from a distantly related mammal (38, 54, 55).
In other words, the nuclear and the mitochondrial genomes must
co-evolve to encode proteins that are compatible in the complexes of
the electron transport chain. The MWFE protein is found in the membrane
subcomplex, and hence it is probable that it interacts with one or more
of the mtDNA-encoded proteins. Additional fractionations suggest that
it is associated with the I
subcomplex (17), and therefore the
subunits ND1, ND2, ND3, and ND4L are likely candidates. Because the
extra-membranous domain of MWFE is highly charged, it must interact
with a hydrophilic, extra-membranous domain (a loop or terminal
segment) of one or more of these integral membrane proteins.
An unsolved problem is to determine the orientation of the MWFE protein
in the inner mitochondrial membrane. It should be noted that it is
imported without further processing. The transmembrane domain may
therefore serve both as the mitochondrial targeting sequence and as the
membrane anchor. If the N terminus is inserted as in a normal import
pathway for mitochondrial matrix proteins, one would predict the
hydrophilic domain to extend into the intermembrane space. Preliminary
results with a MWFE-GFP chimeric protein support such an
interpretation, but this protein is not functionally active. The fully
functional MWFE-HA proteins described in this report will be very
useful in the determination of the orientation of this protein.
A detailed comparison of the hamster (rodent) protein with the human
(primate) MWFE protein suggested a very small segment (amino acids
39-46) where significant sequence differences were observed. The human
protein is not functional in a complementation test with a hamster null
mutant. This segment must be involved in a critical interaction, making
the human protein incapable of functioning with the other subunits
encoded by the hamster mtDNA and nDNA. The finding that the human
protein is highly unstable in the hamster mitochondria strengthens this
conclusion (see below). The focus on this segment of the protein is
further validated by our finding that a change of two amino acids in
this segment can have a noticeable effect on complex I activity. First,
when the hamster protein is altered in the direction toward the human sequence (e.g. A41/42), the activity is decreased relative
to the wild type hamster protein. The A41/42 mutant protein also resembles the less active mouse protein with a reduced charge at
position 42. Second, a change of two amino acids in the human protein
(U41/42) can convert the totally inactive and unstable protein into a
partially functional and more stable protein in hamster mitochondria.
The U41/42 mutant protein has positively charged side chains at
positions 40 and 42, like the hamster protein, and an additional
positive charge at position 44. In the inverse experiment in human
cells, hamster and mutated MWFE proteins are unstable, and two amino
acid substitutions convert the stable human protein into an unstable protein.
The MWFE protein is stable at steady state levels when it is
incorporated into complex I but is highly labile as an isolated subunit
in mitochondria. The level of MWFE protein therefore may also reflect
the level of assembled complex I. In a mutant (V79-G7) defective in
mitochondrial protein synthesis the protein cannot be detected at
steady state levels, although the V79-G7 mutant cells can complement
the CCL16-B2 mutant in somatic cell hybrids. In the V79-G7 mutant all
seven mtDNA-encoded subunits of complex I are absent. As expected,
overexpressed MWFE is also undetectable in V79-G7. Similarly, in mouse
mutant cells defective in single, mitochondrially encoded proteins ND5
or ND6, little or no complex I activity is detected (18). An inactive
complex I is, however, assembled in the ND5 mutant. We detect
correspondingly little or no MWFE protein at steady state in ND6 cells,
but MWFE is present in ND5
cells.2 Other mutant alleles
of the NDUFA1 gene encode single amino acid substitutions
(V79-G20) or small C-terminal deletions (V79-G14). In these mutants
there is no complex I activity, and there is also no detectable MWFE
protein (although in V79-G14 the antigenic determinant may have been
destroyed). In this case all the other subunits of complex I are made,
but the mutant protein presumably cannot become integrated and hence
protected against degradation.
Several of the mutant forms of the MWFE protein were shown here to
yield a reduced complex I activity when introduced into the CCL16-B2
null mutant. There are several possible explanations. The mutant MWFE
protein could be incorporated normally into complex I, but it could
interfere partially with some of the conformational motions associated
with complex I activity/turnover. The effect would be a lowering of the
specific activity of complex I. Alternatively, the incorporation of a
mutant MWFE protein into the complex could be slowed down. If assembly
or degradation are alternative fates, degradation would be favored by a
slower assembly. Results shown in Fig. 7 point in this direction. A
lower activity would then be the result of less active complex being
produced. One can also consider that the association of the MWFE
protein with complex I is a dynamic one. The MWFE protein could diffuse
in the plane of the membrane; its lateral association with a domain of
the complex through interactions outside of the membrane would be critically dependent on charges and charge distributions and possibly the conformation of the extra-membranous domain. Mutant and wild type
proteins can be expected to differ with regard to these parameters. Again, "free" MWFE protein would be subject to rapid degradation. This issue also becomes relevant in a discussion of how the MWFE protein is incorporated into the complex during or after its import into mitochondria. Is it first inserted into the membrane and then
associated with an assembled or partially assembled complex I, or does
the partially assembled complex constitute a direct target for import?
Western analyses and complex I activity measurements by polarography
are unfortunately not sufficiently precise to distinguish between a
lower specific activity and a reduced amount of complex I. The presence
or absence of activity and/or MWFE proteins in the various mutants can
be clearly established, but a precise correlation between differences
of less than a factor of 2 is technically challenging.
The MWFE proteins were expressed from several different transgenes with
strong constitutive promoters, yielding 5-10-fold elevated levels of
mRNA relative to the endogenous NDUFA1 mRNA level.
There is no corresponding increase in the level of MWFE protein
detectable on Western blots. It is very plausible that all the excess
MWFE protein that cannot be assembled is rapidly turned over by one or
more mitochondrial proteases. These results also suggest that MWFE may
not be a limiting factor in the assembly of active complex I. Based on
Northern analysis, the wild type or mutant transgenes were expressed at
significantly higher levels than the endogenous NDUFA1 gene.
Nevertheless, complex I activity in transfected CCL16-B2 cells
generally did not exceed the activity of wild type untransfected cells
(see below), and when mutant alleles were expressed, the activity was
reduced, depending on the mutation. It is therefore less likely that
kinetic effects are responsible for reduced activity.
Some interesting and relevant observations were made when wild type and
mutant HA-tagged MWFE protein was expressed in wild type cells,
i.e. expression from the transgene contributed to the pool
of proteins also expressed from the endogenous gene. One prediction was
that a mutant allele should behave as a dominant negative mutation,
leading to reduced complex I activity and slower growth on DME-Gal.
Such clones were indeed found, but a generalization of this result was
complicated by the observed clonal variations. Fast growing clones with
relatively high complex I activity were present as well as slow growing
clones with significantly less activity. These clones were picked up
because with the polycistronic constructs the selections could be made
in DME-Glu with the drug G418. However, under glucose deprivation or in
DME-Gal one would expect a (pooled) population of cells to evolve in
favor of the faster growing clones.
When wild type MWFE-HA was expressed as well as the endogenous MWFE,
the signal ratio of the two proteins found on Western blots reflected
the abundance of the HA-tagged protein from the more abundant
transcript. In contrast, the A41/42-HA mutant protein appeared to be
less abundant relative to the endogenous MWFE protein, even when the
A41/42-HA transcript levels were much higher. Such a result suggests a
differential stability or assembly rate, with the wild type protein
favored over the A41/42-HA protein. It should be pointed out that these
comparisons are all relative from a single blot such as that shown in
Fig. 7. Because the antibodies are very different, it is not possible
to deduce absolute amounts of the endogenous and HA-tagged MWFE proteins.
Clone B1-A41/42-HA.3 had the highest growth rate in DME-Gal, the
highest complex I activity, and the greatest intensity of both protein
bands on Western blots, whereas clone B1-A41/42.8 represented the other
extreme (Fig. 8). The cells under consideration are pseudo-diploid
established Chinese hamster cell lines. Different clones have shown
significant variations in complex II/III activities which should have
been unaffected by any of the various MWFE proteins being expressed.
Are there adaptations in gene expression during prolonged culture? The
formation of the mitochondrial complex I requires at least 36 nuclear
genes scattered over many different chromosomes. How is their
expression coordinated? It could also be that one of the mitochondrial
gene products becomes limiting but variable among clones. Variations at
any of these loci could account for some of the variations we have observed.
One rationale for using the poly-cistronic expression vector was to
have a drug selection and maintenance of the transgene expression,
whereas the cells could be grown in DME-Glu, where respiration is not
essential. Nevertheless, glucose could become transiently low at higher
population densities, favoring the growth of clones with higher
respiratory capacity.
In conclusion, this paper highlights several aspects of the MWFE
protein in complex I assembly and activity. A stable ~900-kDa complex
detectable on BN-PAGE is not formed in the absence of the MWFE protein.
The MWFE protein is detectable in mitochondria only when it is
incorporated into the complex and protected from proteases in the
presence of ND subunits. Species comparisons and mutagenesis
experiments highlight a small segment of the protein that is involved
in a critical interaction with other complex I proteins. Even though
the protein is highly conserved in evolution, the protein is
non-functional and unstable when the primate protein is expressed in
rodent cells or when the rodent protein is expressed in human cells.
If, as seems likely, the MWFE protein interacts with one or more
mitochondrially encoded proteins, the present example is a highly
specific illustration of the need for compatible nuclear and
mitochondrial genes. Future experiments are aimed at identifying these proteins.
 |
ACKNOWLEDGEMENTS |
We are grateful to Drs. Y. Hatefi, T. Yagi,
A. Matsuno-Yagi, R. Capaldi, and M. David for generously supplying
various antibodies. Drs. Hatefi, Matsuno-Yagi, and Yagi deserve special
thanks for numerous discussions and advice during the execution of this
project. We also thank Drs. G. Attardi and A. Chomyn for sending mouse cell lines (3A-20-4, 4A) with defective ND5 and ND6 mitochondrial genes, respectively. D. Ream-Robinson made numerous contributions to
the construction of various vectors, and E. Hoeptner provided valuable
assistance with tissue culture, transfections, and other procedures. We
thank MitoKor and staff (Dr. A. Murphy) for financial as well as
technical support and encouragement.
 |
FOOTNOTES |
*
This work was supported by grants from the California
BioStar Program with matching contributions from MitoKor (San Diego, CA), grants from the Muscular Dystrophy Association, and Grant GM59909
from the United States Public Health Service.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been
submitted to the GenBankTM/EBI Data Bank with accession
number(s) AF495658, AF495659, and AF495660.
To whom correspondence should be addressed. Tel.: 858-534-2741;
Fax: 858-534-0053; E-mail: ischeffler@ucsd.edu.
Published, JBC Papers in Press, April 5, 2002, DOI 10.1074/jbc.M202016200
2
N. Yadava, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
DME, Dulbecco's
modified Eagle's;
HA, hemagglutinin;
BN, blue native;
TMPD, N,N,N',N'-tetramethyl-p-phenylenediamine.
 |
REFERENCES |
| 1.
|
Yagi, T.,
Yano, T., Di,
Bernardo, S.,
and Matsuno-Yagi, A.
(1998)
Biochim. Biophys. Acta
1364,
125-133[Medline]
[Order article via Infotrieve]
|
| 2.
|
Rasmusson, A. G.,
Heiser, V.,
Zabaleta, E.,
Brennicke, A.,
and Grohmann, L.
(1998)
Biochim. Biophys. Acta
1364,
101-111[Medline]
[Order article via Infotrieve]
|
| 3.
|
Guénebaut, V.,
Schlitt, A.,
Weiss, H.,
Leonard, K.,
and Friedrich, T.
(1998)
J. Mol. Biol.
276,
105-112[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Walker, J. E.
(1995)
Biochim. Biophys. Acta
1271,
221-227[Medline]
[Order article via Infotrieve]
|
| 5.
|
Schulte, U.,
and Weiss, H.
(1995)
Methods Enzymol.
260,
3-14[Medline]
[Order article via Infotrieve]
|
| 6.
|
Finel, M.
(1998)
Biochim. Biophys. Acta
1364,
112-121[Medline]
[Order article via Infotrieve]
|
| 7.
|
Matsuno-Yagi, A.,
and Yagi, T.
(2001)
J. Bioenerg. Biomembr.
33,
155-157[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Friedrich, T.
(2001)
J. Bioenerg. Biomembr.
33,
169-177[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Dupuis, A.,
Prieur, I.,
and Lunardi, J.
(2001)
J. Bioenerg. Biomembr.
33,
159-168[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Schulte, U.
(2001)
J. Bioenerg. Biomembr.
33,
205-212[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Videira, A.,
and Duarte, M.
(2001)
J. Bioenerg. Biomembr.
33,
197-203[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Yagi, T.
(1993)
Biochim. Biophys. Acta
1141,
1-17[Medline]
[Order article via Infotrieve]
|
| 13.
|
Yagi, T.,
Yano, T.,
and Matsuno-Yagi, A.
(1993)
J. Bioenerg. Biomembr.
25,
339-345[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Yamaguchi, M.,
and Hatefi, Y.
(1993)
Biochemistry
32,
1935-1939[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Finel, M.,
Majander, A. S.,
Tyynelä, J., De,
Jong, A. M. P.,
Albracht, S. P. J.,
and Wikström, M.
(1994)
Eur. J. Biochem.
226,
237-242[Medline]
[Order article via Infotrieve]
|
| 16.
|
Yamaguchi, M.,
Belogrudov, G. I.,
and Hatefi, Y.
(1998)
J. Biol. Chem.
273,
8094-8098[Abstract/Free Full Text]
|
| 17.
|
Sazanov, L. A.,
Peak-Chew, S. Y.,
Fearnley, I. M.,
and Walker, J. E.
(2000)
Biochemistry
39,
7229-7235[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Chomyn, A.
(2001)
J. Bioenerg. Biomembr.
33,
251-257[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Ohnishi, T.
(1998)
Biochim. Biophys. Acta
1364,
186-206[Medline]
[Order article via Infotrieve]
|
| 20.
|
Grigorieff, N.
(1999)
Curr. Opin. Struct. Biol.
9,
476-483[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Walker, J. E.
(1992)
Q. Rev. Biophys.
25,
253-324[Medline]
[Order article via Infotrieve]
|
| 22.
|
Walker, J. E.,
Arizmendi, J. M.,
Dupuis, A.,
Fearnley, I. M.,
Finel, M.,
Medd, S. M.,
Pilkington, S. J.,
Runswick, M. J.,
and Skehel, J. M.
(1992)
J. Mol. Biol.
226,
1051-1072[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Soderberg, K.,
Mascarello, J. T.,
Breen, G. A. M.,
and Scheffler, I. E.
(1979)
Somatic Cell Genet.
5,
225-240[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Breen, G. A. M.,
and Scheffler, I. E.
(1979)
Somatic Cell Genet.
5,
441-451[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Seo, B. B.,
Kitajima-Ihara, T.,
Chan, E. K. L.,
Scheffler, I. E.,
Matsuno-Yagi, A.,
and Yagi, T.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
9167-9171[Abstract/Free Full Text]
|
| 26.
|
Au, H. C.,
Seo, B. B.,
Matsuno-Yagi, A.,
Yagi, T.,
and Scheffler, I. E.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
4354-4359[Abstract/Free Full Text]
|
| 27.
|
Zhuchenko, O.,
Wehnert, M.,
Bailey, J.,
Sun, Z. S.,
and Lee, C. C.
(1996)
Genomics
37,
281-288[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Schapira, A. H.
(1998)
Biochim. Biophys. Acta
1364,
261-270[Medline]
[Order article via Infotrieve]
|
| 29.
|
Robinson, B. H.
(1998)
Biochim. Biophys. Acta
1364,
271-286[Medline]
[Order article via Infotrieve]
|
| 30.
|
Loeffen, J. L.,
Smeitink, J. A.,
Trijbels, J. M.,
Triepels, R. H.,
Sengers, R. C.,
and Van den Heuvel, L. P.
(2000)
Hum. Mutat.
15,
123-134[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Smeitink, J. A. M.,
Loeffen, J. L. C. M.,
Triepels, R. H.,
Smeets, R. J. P.,
Trijbels, J. M. F.,
and Van den Heuvel, L. P.
(1998)
Hum. Mol. Genet.
7,
1573-1579[Abstract/Free Full Text]
|
| 32.
|
Loeffen, J. L. C. M.,
Triepels, R. H.,
Van den Heuvel, L. P.,
Schuelke, M.,
Buskens, C. A. F.,
Smeets, R. J. P.,
Trijbels, J. M. F.,
and Smeitink, J. A. M.
(1998)
Biochem. Biophys. Res. Commun.
253,
415-422[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Loeffen, J.,
Smeitink, A.,
Triepels, R.,
Smeets, R.,
Schuelke, M.,
Sengers, R.,
Trijbels, F.,
Hamel, B.,
Mullaart, R.,
and Van den Heuvel, L.
(1998)
Am. J. Hum. Genet.
63,
1598-1608[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Smeitink, J. A. M.,
Sengers, R.,
Trijbels, F.,
and van den Heuvel, J.
(2001)
J. Bioenerg. Biomembr.
33,
259-266[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Scheffler, I. E.
(1986)
in
Carbohydrate Metabolism in Cultured Cells
|